The Use of ESAs in Patients With Breast Cancer
Brian Leyland-Jones, MBBS, PhD, director of Edith Sanford Breast Cancer Research, discusses the use of erythropoiesis stimulating agents (ESAs) in patients with breast cancer.
Brian Leyland-Jones, MBBS, PhD, director of Edith Sanford Breast Cancer Research, discusses the use of erythropoiesis stimulating agents (ESAs) in patients with breast cancer.
There has been a lot of controversy in this space. At the 2013 Breast Cancer Symposium, Leyland-Jones presented the latest meta-analysis, which looked at 9 current studies in breast cancer randomizing ESAs versus no ESAs.
Clinical Pearls
The meta-analysis looked at 5 endpoints and found that mortality increased 20% when using ESAs. In studies with target hemoglobin levels at or less than 12 grams per deciliter (g/dL), the hazard ratio was reduced to 1.03. Leyland-Jones says that when using ESAs, the target hemoglobin levels must be reduced to 12 g/dL to reduce the mortality rate.
- There has been a lot of controversy over the use of ESAs in breast cancer
- The latest meta-analysis looked at 9 current studies which randomized ESAs vs no ESAs
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
